ASH 2022 | Results of Phase II trial of olutasidenib in patients with R/R mIDH1 AML
Jorge Cortes, MD, Augusta University, Augusta, GA, shares insights into the safety profile and efficacy of olutasidenib in patients with IDH1-mutated acute myeloid leukemia (AML), as studied in a recent Phase II trial (NCT02719574). Dr Cortes explains that olutasidenib is a potent IDH1 inhibitor that has been found to lead to high rates of durable complete response (CR) and manageable adverse events. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant for Pfizer, Novartis, Takeda, Sun Pharma, Rigel and Forma Therapeutics. Dr Cortes’ institution receives research support from Pfizer, Takeda, Novartis and Sun Pharma.
